Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest
- PMID: 39335013
- PMCID: PMC11428412
- DOI: 10.3390/antibiotics13090840
Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest
Abstract
Multidrug-resistant Candida auris has recently caused major outbreaks in healthcare facilities. Rapid and accurate antifungal susceptibility testing (AST) of C. auris is crucial for proper management of invasive infections. The Commercial Sensititre Yeast One and Vitek 2 methods underestimate or overestimate the resistance of C. auris to fluconazole and amphotericin B (AMB). This study evaluated the AST results of C. auris against fluconazole and AMB by gradient-MIC-strip (Etest) and broth microdilution-based MICRONAUT-AM-EUCAST (MCN-AM) assays. Clinical C. auris isolates (n = 121) identified by phenotypic and molecular methods were tested. Essential agreement (EA, ±1 two-fold dilution) between the two methods and categorical agreement (CA) based on the Centers for Disease Control and Prevention's (CDC's) tentative resistance breakpoints were determined. Fluconazole resistance-associated mutations were detected by PCR-sequencing of ERG11. All isolates identified as C. auris belonged to South Asian clade I and contained the ERG11 Y132F or K143R mutation. The Etest-MCN-AM EA was poor (33%) for fluconazole and moderate (76%) for AMB. The CA for fluconazole was higher (94.2%, 7 discrepancies) than for AMB (91.7%, 10 discrepancies). Discrepancies were reduced when an MCN-AM upper-limit value of 4 µg/mL for fluconazole-susceptible C. auris and an Etest upper-limit value of 8 µg/mL for the wild type for AMB were used. Our data show that resistance to fluconazole was underestimated by MCN-AM, while resistance to AMB was overestimated by Etest when using the CDC's tentative resistance breakpoints of ≥32 µg/mL for fluconazole and ≥2 µg/mL for AMB. Method-specific resistance breakpoints should be devised for accurate AST of clinical C. auris isolates for proper patient management.
Keywords: Candida auris; Etest; MICRONAUT-AM EUCAST assay; antifungal susceptibility testing; comparative performance.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Similar articles
-
Evaluation of the Vitek 2 system for antifungal susceptibility testing of Candida auris using a representative international panel of clinical isolates: overestimation of amphotericin B resistance and underestimation of fluconazole resistance.J Clin Microbiol. 2024 Apr 10;62(4):e0152823. doi: 10.1128/jcm.01528-23. Epub 2024 Mar 19. J Clin Microbiol. 2024. PMID: 38501836 Free PMC article.
-
Evaluation of the MIC test strips for antifungal susceptibility testing of Candidozyma auris (Candida auris) using a representative international collection of isolates.J Clin Microbiol. 2025 Aug 13;63(8):e0039925. doi: 10.1128/jcm.00399-25. Epub 2025 Jul 3. J Clin Microbiol. 2025. PMID: 40608317 Free PMC article.
-
Overestimation of Amphotericin B Resistance in Candida auris with Sensititre YeastOne Antifungal Susceptibility Testing: a Need for Adjustment for Correct Interpretation.Microbiol Spectr. 2023 Jun 15;11(3):e0443122. doi: 10.1128/spectrum.04431-22. Epub 2023 Apr 10. Microbiol Spectr. 2023. PMID: 37036351 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Commercial Methods for Antifungal Susceptibility Testing of Saprophytic Molds: Can They Be Used to Detect Resistance?J Fungi (Basel). 2024 Mar 14;10(3):214. doi: 10.3390/jof10030214. J Fungi (Basel). 2024. PMID: 38535222 Free PMC article. Review.
Cited by
-
Diagnostic Approaches for Candida auris: A Comprehensive Review of Screening, Identification, and Susceptibility Testing.Microorganisms. 2025 Jun 24;13(7):1461. doi: 10.3390/microorganisms13071461. Microorganisms. 2025. PMID: 40731971 Free PMC article. Review.
-
Candida vulturna, the Next Fungal Menace? A Narrative Review.Mycoses. 2025 May;68(5):e70070. doi: 10.1111/myc.70070. Mycoses. 2025. PMID: 40396413 Free PMC article. Review.
-
Identification and antifungal resistance profiling of Candida (Candidozyma) auris in a tertiary hospital in Istanbul, Türkiye.Ann Saudi Med. 2025 Jul-Aug;45(4):207-217. doi: 10.5144/0256-4947.2025.207. Epub 2025 Aug 7. Ann Saudi Med. 2025. PMID: 40753464 Free PMC article.
-
The multidrug-resistant Candida auris, Candida haemulonii complex and phylogenetic related species: Insights into antifungal resistance mechanisms.Curr Res Microb Sci. 2025 Jan 28;8:100354. doi: 10.1016/j.crmicr.2025.100354. eCollection 2025. Curr Res Microb Sci. 2025. PMID: 39995443 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources